The role of Actiphage® as a powerful research tool for tuberculosis-related diseases is to be explored at the 15th International Association for Paratuberculosis Colloquium (ICP 2022) in Dublin on 12 – 16th June 2022.
Results from a study of co-infection of bison will be presented and the new Johne’s Disease Testing Service will be discussed on the Biosellal stand where PBD Biotech has a presence.
The robust nature of the mycobacteria means that physical or chemical lysis methods are inefficient. In contrast, the phage lysis has evolved to be highly efficient.
Actiphage uses bacteriophage as the lysing agent to extract DNA from viable mycobacterial cells ahead of identification with PCR, and a further poster will discuss optimising the technique for different hosts.
Paratuberculosis, sometimes called MAP or Johne’s Disease. is recognised as one of the most important infectious diseases affecting livestock production across Ireland and results in significant loss of production.
Ireland has developed a program of research into paratuberculosis across several institutes including: University College Dublin, Queen’s University Belfast, Cork Institute of Technology, AFBINI, and the Central Veterinary Research Laboratory of the Department of Agriculture so it is fitting that it should host the conference in Dublin.
